Burcon NutraScience Q3 2026 Earnings Call Transcript

Quartr
Provided by Quartr
February 11, 2026

Key Takeaways

  • Positive Sentiment: Q3 revenue was CAD 740,000 (a doubling vs. Q2) and cumulative calendar‑2025 revenues reached CAD 1.4M, meeting guidance; management reaffirmed guidance for double‑digit revenue and to be cash‑flow positive by end of calendar 2026.
  • Positive Sentiment: Commercialization progress includes >200 active customer projects and recurring monthly ingredient sales, with management saying the current facility and order book provide clear line‑of‑sight to quarter‑over‑quarter growth driven mainly by their own protein products.
  • Neutral Sentiment: Burcon announced a convertible note offering up to CAD 6.9M (first tranche CAD 1.25M closed) with insiders and its manufacturing partner participating; management expects the final tranche to close after the Feb 20 shareholder meeting and says proceeds will accelerate capacity and sales.
  • Positive Sentiment: The company emphasizes a differentiated, IP‑protected technology platform (high‑purity proteins: Peazazz, FavaPro, Solatein, Puratein) that supports multi‑protein blends and new product launches, which management argues fits current market demand and should support margins.
AI Generated. May Contain Errors.
Earnings Conference Call
Burcon NutraScience Q3 2026
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

Good afternoon, everyone, and thank you for participating in today's conference call to discuss Burcon NutraScience Corporation Fiscal 2026 third quarter conference call. Joining us today are Kip Underwood, Burcon's Chief Executive Officer, and Alex Varty, the company's Interim Chief Financial Officer. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star one, then the following on your telephone keypad. Should you need assistance during the presentation, you may signal an operator by pressing star zero. Then before we conclude today's call, I provide the company's safe harbor statement with important cautions regarding the forward-looking statements made during this call. Now, I would like to turn the call over to CEO of Burcon, Mr. Kip Underwood. Sir, please go ahead.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Thanks, John. Good morning, good afternoon, and good evening to all on the call, and thank you for your time today and your investment in Burcon. At the conclusion of our presentation, we hope you walk away with three really important takeaways. The first is we are targeting an exciting, growing market. The second is customer responses, either with their time in projects or in their purchase decision in buying our products, validates both our strategy and the performance of our products. And lastly, maybe most importantly, we're on plan. Today, we will walk through that we had performance within our calendar 2025 guidance, and we will certainly affirm our calendar 2026 guidance of double-digit revenue and cash flow positive by the end of calendar 2026. Our standard safe harbor statement.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

To walk through this discussion today, obviously, we'll go through the highlights of our fiscal Q3. We'll touch on our technology platform. We'll talk about the exciting market we are targeting, I just mentioned. A little update on sales, our sales growth, our current raise, which we expect to close here in a matter of a few weeks. Why we believe Burcon is really a tremendous investment opportunity, and look for what is our path to profitability. At the end, we will have plenty of time for questions and closing remarks. For our fiscal Q3, the operational highlights. You know, with sales growth, it's not just sales growth, it's the underlying multiple customers across multiple products, across multiple food types. So diversity of growth that is all fully aligned with our strategy. We've launched, scaled, optimized multiple products with our partner at our manufacturing facility.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Really through our customer project funnel. We talk a lot when customer projects take 9-18 months to come to fruition, from a contact to converting to business. So we are always building for the future. Those projects we develop today, as you can see, over 200 customer projects, those projects we build today truly drive sales tomorrow. With that, I'll turn it over to Alex, our CFO, for the financial highlights. Alex, take it away.

Alex Varty
Alex Varty
Interim CFO at Burcon NutraScience

Thank you, Kip. Starting off, Burcon had a strong quarter, generating $740,000 of revenue in Q3, which represents a doubling of the revenues generated in Q2. At the end of calendar 2025, we generated cumulative revenues of CAD 1.4 million, which meets our revenue guidance. Pausing on that for a moment, I want to underscore the progress made through calendar 2025. We started that calendar year without a production facility, and we're ending the calendar year meeting our revenue target and with a 100% quarter-over-quarter growth rate in revenues. Looking forward, we further expect substantial revenue growth through calendar 2026, and we have a robust customer order book for sales that support that growth. As we focus our efforts and our resources on production and on sales, we've also reduced our other spending.

Alex Varty
Alex Varty
Interim CFO at Burcon NutraScience

So in respect of research and development, we see a 44% year-over-year decrease of Q3 spend. And in general and administrative expenses, we see a 22% reduction when you compare it to fiscal Q3 in the prior year. Lastly, we've announced the offering of our convertible notes of up to CAD 6.9 million, which is supported by, with significant participation from insiders and owners of our manufacturing partner. On December 31, we closed the first tranche of this offering, raising proceeds of CAD 1.25 million, and we expect the final tranche to close in the last week of February, following the special shareholder meeting to be held on February 20, 2026. We'll speak a bit more about this offering in detail later on. I'll turn it back to Kip now to talk through our technology platform.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Thanks, Alex. Our technology platform is the foundation for our success, and this is really, you know, the foundation for our growth and our future. And what our technology platform fundamentally does is delivers purity, the highest purity we see in the marketplace today for plant proteins. And that purity leads to performance. Performance means we work with food companies to deliver better-tasting products to consumers, the ones that we eventually, you and I eventually all buy at the grocery store or the restaurant. That technology platforms apply to multiple products. You see here, the four we have talked about. So we have Solatein, from sunflower, protein from the sun, Peazazz, our pea protein, FavaPro, our fava protein, and Puratein, our canola protein.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

These are all highly differentiated based upon that purity, and when you look at things like FavaPro and into Solatein, our sunflower protein, you're looking into really new to the world type products. What's even more exciting, we don't talk about it very much now, is there is a R&D pipeline behind these of future innovations to come that will drive growth into, into the future. And lastly, it's important to note, this technology is fully protected by an intellectual property moat to ensure we, we can drive growth, protected growth, not just today, but into, into tomorrow. At the outset, I mentioned we are targeting an exciting market. In short, protein is hot. If you've watched television commercials or you've been in a grocery store, you have seen a substantial change or improvement or more products with protein positioning.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

And that's truly driven fundamentally by health benefits, the benefits of a higher protein diet from a strength, from a health, from a everyday life perspective. And then that growth is accelerated by those consumers who are on GLP-1 weight loss medication. Those consumers need more protein across less calories, and food companies are reacting to that end consumer need. Where food companies are reacting is a bull's-eye for our technology platform, our differentiation. Our differentiation is spot on with what food companies are trying to do, and it's highly relevant in helping them meet those new consumers' needs. As evidence of that, we see our customers voting with their pocketbook. So significant quarter-on-quarter growth, as you can see, over 200 active customer projects. And I think it's really important to see these have great diversity.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

So a lot of these projects and our current sales are with more entrepreneurial, cutting-edge brands. Those brands that are on the edge of the trend, their values are typically better aligned with ours. They move quickly, they make decisions quickly, think faster, cash for us, very aligned. There are also some customers and brands in there that everybody on the phone here would probably recognize. Beyond the types of customers, it's types of foods. So think about a ready-to-mix powder that somebody makes at home. Think about a ready-to-drink beverage, a liquid beverage that has a protein positioning, maybe 10 or 15 grams per serving. Think about nutrition bars. All of those are areas where we're working with customers where our protein differentiation is relevant.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

And then lastly, in plant-based foods, where companies are trying to make plant-based foods just better to attract more end consumers, our technology, our purity, helps them deliver against the taste expectations of new consumers. So certainly strong sales growth with our robust sales funnel, more to come, and we look forward to talking more about customers into the future. Alex mentioned the current fundraise we have going on. We expect to close this right after our shareholder meeting on February twentieth. And beyond the details, what we get asked a lot is why? And at its core, this is to accelerate growth. We see the customers we have today, we see the recurring sales today. To remind everybody, sales in this industry, once you achieve a sale, it's pretty much always a recurring sale.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

So as a food company makes the product month-on-month, they come back and buy ingredients from us month-on-month. So we see the recurring sales growth, we look at our robust sales funnel, we see that protein is hot in the market, and with our boards, we need to accelerate investment to get ahead of the sales growth. And that is what this raise is all about. So how do we build operating days sooner? How do we expand capacity sooner? How do we build to ensure as we close these customer projects and that growth comes, that we are there and ready to meet, if not exceed, those customers' expectations? As I mentioned, exciting market, pea platform, foundational, delivering a highly differentiated offering to that market. We're seeing, and we have customers right now, we're seeing that growth with recurring sales.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

And we put that together and we believe, I believe, that Burcon is an exciting investment opportunity. We're substantially de-risked from where we were nine months ago. Alex went through the progression over the last year. We can see the tremendous opportunity in front of us, and I think we're also hopefully building a track record. It's important to us that we say what we do, and we do what we say. We laid out our guidance for calendar 2025, the first time we've done that, and we're right in the middle of the range, and we are certainly affirming our guidance for 2026, double-digit revenue and cash flow positive by the end of calendar 2026.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Certainly believe exciting times are on the horizon for us and hope those who aren't invested in this come along with us for this ride. I mentioned our guidance for calendar 2026. The two headlines here are double-digit revenue and cash flow positive, and fundamentally, what drives that? We are very focused on the basics of production and sales. The market is there, the demand is there, and it's on us to deliver. As we close more customer projects, these are recurring sales, they build on each other. We're targeting these types of customers where we're highly differentiated, allows us to continue to drive good margins, always working on capacity and always working on efficiency, both to control costs, but more importantly, to move faster to stay ahead of the growth curve.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

With that, John, I will turn it over, back to you for any questions from our audience.

Operator

Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press star followed by the number 1 on your touch-tone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press star followed by the number 2. If you're using a speakerphone, please lift the handset before pressing any keys. Your first question comes from the line of Dave Storms from Stonegate. Your line is now open.

Dave Storms
Director of Equity Research at Stonegate

Good evening, and thank you for taking my questions. Hi. I wanted to start with the efficiency comment that you made towards the end of your prepared remarks there. Is there any more you can tell us about maybe the J-curve that you're seeing, as it relates to, you know, sales and startup costs associated with bringing on new customers, and maybe if there's any shallowing of that J-curve as you continue to learn?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Well, I think what we're at a point in growth where I can say is, you know, our fundamental costs don't change all that much as we grow from here forward. So, you know, we have the staff on site to drive and run the facility. We have the infrastructure to go run the business. So, you know, the growth that happens between now and the end of the year really comes with obviously increasing variable costs, but really very little increase in other costs associated. So when we drive efficiencies, that's a lot of that piece. And then just the operational side, we're nine months in, we've learned a lot. We're just better, you know, at operating by hour, by shift, by day, by week.

Dave Storms
Director of Equity Research at Stonegate

That's great. I appreciate it. I did also want to then turn to maybe some of the puts and takes on your stated, you know, plans for double-digit revenue growth in the year. Maybe just if you could help us understand a little more about how much of that might come from expansion within customers, you know, acquiring new customers-

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Mm-hmm.

Dave Storms
Director of Equity Research at Stonegate

And then maybe just any visibility, you know, is that a 6-month visibility you have? Is that a 3-year visibility? You know, anything there would be very helpful.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Sure. So thinking about the so first, our customer, our sales funnel is of a size and scope that, that fully discounted for probably success, easily drives the growth. So that's the, that's the first piece. The second piece, from a growth perspective, 65%-70% of that growth, those customers have already bought at least something from a recurring perspective. And then the balance is, you know, late stage customer work. Again, I would always say they don't. When we say late stage, we've been working with these customers for 9 or 12 months right now. So we have very good line of sight of what their plans are. Therefore, we have good line of sight if they're not buying right now, when they will start. And then I would say, and they build, right?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

So again, these are recurring sales. So if you take a run rate for any quarter, think about, that's the baseline going into the next quarter, and then it grows from there. And then the last thing you mentioned, growth. The customers we are working with are all targeting and launching new products in this growing market that I talked about. So we would also anticipate that most of them will then have success and capture that growth. So as they grow, obviously, we grow as well.

Dave Storms
Director of Equity Research at Stonegate

Understood. That's, that's incredibly helpful. And just so I'm clear on that, when you mention customers targeting and launching new products, how much or is there any interplay, you know, across your entire portfolio, or do you tend to see customers sticking to, to one form of protein, if that question makes sense?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Actually, I think what we see, which is great for us. I think traditionally it has been one form of protein. What we're seeing in the marketplace right now is blends of proteins, 'cause each protein from each plant has a little bit different strengths. And oftentimes, when you add a pea protein to canola protein to a, let's say, a fiber protein, you know, one plus one plus one could be five. Their strengths actually really are synergistic together, and we're seeing food companies take advantage of that, which is also good for us because we are one of the few companies out there that have truly a technology platform that can be applied and is applied to multiple products. So we can become kind of a one-stop shop. You want to do a blended proteins, great! We can cover that.

Dave Storms
Director of Equity Research at Stonegate

Understood. That, I really appreciate that. One more, if I could. Would just love to touch on any thoughts around financing needs in the balance sheet. I know you have that upsized private placement coming down the pipe. There was a release about, you know, extending your warrants. Just maybe any further comments about your comfortability with your balance sheet and if you think there's enough there to continue the growth or if you'll need to hit the markets again.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Yeah, we believe once we close the raise here in a few weeks, that, you know, we'll have the balance sheet to accelerate growth. So we don't have anything planned on the horizon at all. We will always, at the same time, always look for like, if there's a way to grow faster, to do something fundamentally different, then we'll evaluate that. But on the current plan, we're in good shape, Dave.

Dave Storms
Director of Equity Research at Stonegate

Thank you for taking my questions, and good luck in the next quarter.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Thanks, I appreciate it.

Operator

As a reminder, if you have any questions, please press star one. There are no further questions at this time on the phone lines. I will now turn the call over to Paul Lam, Director of Investor Relations and Communications, for our webcast questions. Please continue.

Paul Lam
Paul Lam
Director of Investor Relations and Communications at Burcon NutraScience

Thanks, John. We have a few questions from the webcast today. This one coming from Bruce Lisenby, a private investor. In terms of revenue, what is the maximum the existing facility could deliver, assuming a 24/7 shifts and realistic improvements in processes and equipment?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Hey, thanks, Bruce. What we can say is that the facility as it sits, especially with the last 10 months of experience, it has the size and the scope and the revenue to do a few things. One, delivers us well into profitability and well into a very good margin space. To a size and scope that is relevant, not just to the customer we're targeting today, those entrepreneurial, more cutting-edge brands, but also highly relevant to a scale of a, you know, of a major food company that all of us might know, top of mind. So what we can say, certainly fully, gets us well into profitability and well beyond the guidance of double-digit revenue in 2026.

Paul Lam
Paul Lam
Director of Investor Relations and Communications at Burcon NutraScience

Thank you, Kip. That answer actually leads us into the next question, which comes from David Gatchens, private investor. What is the targeted time for corporate profitability? And I, I know we touched on that before, but, do you have any further insight into that?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Yeah, I think it's good to reiterate. So our guidance for calendar 2026 is double-digit revenue and cash flow positive. And, you know, fundamentally, we certainly have the capacity and the people on site with our manufacturing partner to do that. We have the combination of the order book and our sales funnel to drive the demand side. So really, to get to profitability, cash flow positive, in calendar 2026, what we basically do is execute our plan, and that's what we intend to do.

Paul Lam
Paul Lam
Director of Investor Relations and Communications at Burcon NutraScience

Okay, thank you, Kip. Next question comes from a private investor. "Congratulations on the sales momentum. Can you give us more color on the product mix of your current sales? Are you selling more pea protein, canola protein, or fava protein, and do you expect this mix to change going forward?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Thank you for the question. So at the current time, we sell more pea protein. This was certainly our ongoing strategy. Pea protein is the largest current market. As we move forward over time, let's think year two, year three, we believe we will see more of a growth from our sunflower protein. New to the world, highly differentiated, very exciting, and more growth in our fava protein. Also, a more differentiated, more new to the world technology. So we start with pea protein, current largest market. That was our strategy to begin with, quicker to sales. And then as we move forward into year two, year three, we'll see a larger presence for sunflower protein. It's protein from the sun. It's fantastic. And our fava pro, our fava protein.

Paul Lam
Paul Lam
Director of Investor Relations and Communications at Burcon NutraScience

Okay, thanks for that, Kip. Next question comes from Harry Hermanz. "Hi, congrats on the successful quarter. As a shareholder, my concern is the share price. Volume is extremely low, and the stock price has stalled. Without major partnership announcements, the stock price is not expected to be close to historic highs. What are you, you planning to do? Do you think." And this is part of his, question as well, too. "Do you think with CAD 30 million in revenue, we could get close enough to historic highs?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Harry, thanks for the question. So what we believe and, and what we're being told is, you know, in the market today, and even as a food technology company, that what we really have to do is deliver results, right? So it's, it's the market rewards less on hope and more on results. So we're very focused on the commercialization of technology, the proven technology, and really turning that into production and sales. And we believe as we continue to, you know, say what we do, do what we say, hit our numbers, drive revenue growth, drive to profitability, that the market, over time will take notice.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

That being said, we're also always looking at how do we do better, a better job of getting the word out to ensure that the capital markets, the investment community, is aware of us and, and, you know, believes what we're capable of and hopefully makes an investment decision to join us.

Paul Lam
Paul Lam
Director of Investor Relations and Communications at Burcon NutraScience

Okay. Thank you, Kip. I think this might be the last question from the webcast. Is it reasonable to expect revenue to continue growing quarter over quarter from here on out? And if yes, will the growth be primarily attributed to protein sales versus contract manufacturing revenue?

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Yes, it is reasonable. We have to drive quarter-on-quarter growth in sales, and we would expect the vast, vast, vast majority of that to be growth of our own products. So again, we have, we have existing recurring sales, existing customers whose sales we expect to grow, and we have a robust sales funnel of you know, all customers evaluating our products, our technology, and we expect that to drive 95, if not 100% of the growth from here on out.

Paul Lam
Paul Lam
Director of Investor Relations and Communications at Burcon NutraScience

Okay. Thank you, Kip. That's all for our questions from the webcast. John, passing it back over to you.

Operator

Thank you, everyone. That's all the time we have for questions today. At this time, this concludes our question and answer session. I would now like to turn the call back over to Mr. Underwood for any closing remarks. Please go ahead.

Kip Underwood
Kip Underwood
CEO at Burcon NutraScience

Thanks, John, and first and foremost, thank you to our shareholders for your continued support and investment in Burcon. The confidence you place in us is not lost on us, and we take that responsibility very seriously. A special thanks to our teams. The teams on the ground, they're working their tail off. They're dedicated, they're committed to delivering the results that we've all committed to. We put the support from our shareholders together with the work effort and commitment from our team, and we believe we are well on our way to becoming a profitable food tech company, and I thank everybody again for coming along that journey with us. Back to you, John.

Operator

Before we conclude today's call, I would like to take a moment to read the company's safe harbor statement. This call contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties, and other factors that could cause actual results, performances, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as anticipate, intend, plan, goal, project, estimate, expect, believe, future, likely, can, may, should, could, will, potentially, and similar references to future periods. All statements other than statements of historical fact included during the call are forward-looking statements.

Operator

There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic market and business conditions, regulatory changes, and other risks and factors detailed herein and from time to time in the filings made by Burcon with the securities regulators and stock exchanges, including in the section entitled Risk Factors in Burcon's Annual Information Form, filed with the Canadian Securities Administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date which it was made and except as may be required by applicable securities laws.

Operator

Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements. Finally, I would like to remind everyone that this call is being recorded, and the webcast will be available for replay on the company's website starting later this evening. Thank you, ladies and gentlemen, for joining us today for our presentation. You may now disconnect.

Executives
    • Alex Varty
      Alex Varty
      Interim CFO
    • Kip Underwood
      Kip Underwood
      CEO
    • Paul Lam
      Paul Lam
      Director of Investor Relations and Communications
Analysts
    • Dave Storms
      Director of Equity Research at Stonegate
Powered by Quartr